Amdocs Limited Reports Record Revenue of $706 Million

Amdocs Reports 18% Growth in Quarterly Diluted Non-GAAP Earnings Per Share to $0.52; Diluted GAAP Earnings Per Share of $0.40

* Second quarter revenue increased 18% to $706 million
* 18% increase in second quarter diluted non-GAAP EPS, excluding acquisition-related costs, restructuring charges and equity-based compensation expense, net of related tax effects, to $0.52
* Diluted GAAP EPS of $0.40
* Amdocs was awarded a significant managed services contract by AT&T
* Acquisition of SigValue Technologies, Inc. expands Amdocs offering for fast-growing emerging markets
* Third quarter fiscal 2007 guidance: Expected revenue of approximately $710-$720 million and diluted non-GAAP EPS of $0.50 - $0.52, excluding acquisition-related costs and approximately $0.05-$0.06 per share of equity-based compensation expense, net of related tax effects. Diluted GAAP EPS is expected to be approximately $0.38-$0.41
* Reiterated fiscal 2007 guidance: Expected revenue of approximately $2.83–$2.91 billion and diluted non-GAAP EPS of $2.02-$2.12, which exclude acquisition-related costs, restructuring charges and approximately $0.21-$0.24 per share of equity-based compensation expense, net of related tax effects. Diluted GAAP EPS is expected to be approximately $1.54-$1.68

St. Louis, MO – April 26, 2007 – Amdocs Limited (NYSE: DOX) today reported that for the quarter ended March 31, 2007, revenue was $706.4 million, an increase of 17.5% from last year’s second quarter. Net income on a non-GAAP basis was $114.5 million, or $0.52 per diluted share (excluding acquisition-related costs, which include amortization of purchased intangible assets, in-process research and development write-off and other, and excluding restructuring charges and equity-based compensation expense, net of related tax effects, of $27.3 million), compared to non-GAAP net income of $95.5 million, or $0.44 per diluted share, in the second quarter of fiscal 2006 (excluding acquisition-related costs, which include amortization of purchased intangible assets, and equity-based compensation expense, net of related tax effects, of $13.8 million). The Company’s GAAP net income was $87.2 million, or $0.40 per diluted share, compared to GAAP net income of $81.8 million, or $0.38 per diluted share, in the second quarter of fiscal 2006. Free cash flow for the quarter was $57.9 million, comprised of cash flow from operations of $91.2 million less $33.3 million in net capital expenditures.

“We are pleased to report another successful quarter for Amdocs as we continue to execute,” said Dov Baharav, chief executive officer of Amdocs Management Limited. “Revenue is at record levels and earnings growth is strong. During the quarter we formally launched our Amdocs 7 suite of products which are generating wins for Amdocs. We are delivering solutions and therefore we are expanding our relationship with key customers as they transform their businesses to address convergence, competition and consolidation. While the timing of individual projects can be difficult to predict, the ongoing trend is clear. Transformation activity is driving demand for our products and services today and should provide Amdocs with growth opportunities for years to come.”

Amdocs new business included a variety of wins across geographies and lines of business. These wins include an important managed services contract with AT&T to provide application management services in support of their legacy ordering and wholesale platforms, including software development, testing and production support. In the broadband cable and satellite market, the Company’s wins included subscriber conversions onto an Amdocs system . For an existing customer in Europe, Amdocs has been engaged to provide a CRM solution for multiple market segments. Amdocs continues to grow its OSS business with projects including license and services for customers around the globe, including several new logos.

At the end of its first fiscal quarter, the Company projected that its diluted GAAP EPS for the fiscal quarter ending March 31, 2007 would be $0.35 to $0.39. The Company anticipated that its non-GAAP EPS would be $0.49 to $0.51, excluding acquisition-related costs (which include amortization of purchased intangible assets, in-process research and development write-off and other), and excluding restructuring charges and equity-based compensation expense, net of related tax effects.

As reported, GAAP EPS per diluted share for the second quarter of fiscal 2007 was $0.40. Non-GAAP EPS per diluted share was $0.52 for the quarter, excluding acquisition-related costs (which include amortization of purchased intangible assets, in-process research and development write-off and other), and excluding restructuring charges and equity-based compensation expense, net of related tax effects. The excluded pre-tax restructuring charges amounted to approximately $6 million, reducing GAAP EPS per diluted share by $0.02. The charges consist primarily of severance and other employment related obligations incurred in connection with Amdocs’ measures designed to align its operational structure to its expected future growth and to improve efficiency.

Financial Outlook

Amdocs expects that revenue for the third quarter of fiscal 2007 will be approximately $710-$720 million. Diluted earnings per share on a non-GAAP basis for the third quarter are expected to be $0.50-$0.52, excluding acquisition-related costs and approximately $0.05-$0.06 per share of equity-based compensation expense, net of related tax effects. Diluted GAAP EPS is expected to be approximately $0.38-$0.41.

Reiterated fiscal 2007 guidance: Expected revenue of approximately $2.83-$2.91 billion and diluted non-GAAP EPS of $2.02-$2.12, which excludes acquisition-related costs, restructuring charges and approximately $0.21-$0.24 per share of equity-based compensation expense, net of related tax effects. Diluted GAAP EPS is expected to be approximately $1.54-$1.68.

Amdocs will host a conference call on April 26, 2007 at 5 p.m. Eastern Time to discuss the Company’s second quarter results. The call will be carried live on the Internet via www.InvestorCalendar.com and the Amdocs website, www.amdocs.com.

Non-GAAP Financial Measures

This release includes non-GAAP diluted earnings per share and other non-GAAP financial measures, including free cash flow, non-GAAP cost of service, non-GAAP research and development, non-GAAP selling, general and administrative, non-GAAP operating income, non-GAAP income taxes and non-GAAP net income. These non-GAAP measures exclude the following items:

* amortization of purchased intangible assets;
* in-process research and development write-off and other;
* restructuring charges;
* equity-based compensation expense; and
* tax effects related to the above.

These non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. In addition, these non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. Amdocs believes that non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with Amdocs’ results of operations as determined in accordance with GAAP and that these measures should only be used to evaluate Amdocs’ results of operations in conjunction with the corresponding GAAP measures.

Amdocs believes that the presentation of non-GAAP diluted earnings per share and other financial measures, including free cash flow, non-GAAP cost of service, non-GAAP research and development, non-GAAP selling, general and administrative, non-GAAP operating income, non-GAAP income taxes and non-GAAP net income, when shown in conjunction with the corresponding GAAP measures, provides useful information to investors and management regarding financial and business trends relating to its financial condition and results of operations as well as the net amount of cash generated by its business operations after taking into account capital spending required to maintain or expand the business.

For its internal budgeting process and in monitoring the results of the business, Amdocs’ management uses financial statements that do not include amortization of purchased intangible assets, in-process research and development write-off and other, restructuring charges, equity-based compensation expense, and related tax effects. Amdocs’ management also uses the foregoing non-GAAP financial measures, in addition to the corresponding GAAP measures, in reviewing the financial results of Amdocs. In addition, Amdocs believes that significant groups of investors exclude these non-cash expenses in reviewing its results and those of its competitors, because the amounts of the expenses between companies can vary greatly depending on the assumptions used by an individual company in determining the amounts of the expenses.

Amdocs further believes that, where the adjustments used in calculating non-GAAP diluted earnings per share are based on specific, identified amounts that impact different line items in the Consolidated Statements of Income (including cost of service, research and development, selling, general and administrative, operating income, income taxes and net income), it is useful to investors to understand how these specific line items in the Consolidated Statements of Income are affected by these adjustments.